Metabolic complete tumor response in a patient with epidermal growth factor receptor mutant non-small cell lung cancer treated with a reduced dose of afatinib

Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are the first-line treatment for EGFR-mutant non-small cell lung cancer. Toxicities related to EGFR-TKIs include skin rash, paronychia, and diarrhea, which in some cases can lead to dose reductions or treatment inter...

Descripción completa

Detalles Bibliográficos
Autores principales: Puliafito, Ivana, Esposito, Francesca, Raciti, Gabriele, Giuffrida, Paolo, Caltavuturo, Claudia, Colarossi, Cristina, Munao, Stefania, Sciacca, Dorotea, Giuffrida, Dario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943310/
https://www.ncbi.nlm.nih.gov/pubmed/35291829
http://dx.doi.org/10.1177/03000605211058864

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943310/
https://www.ncbi.nlm.nih.gov/pubmed/35291829
http://dx.doi.org/10.1177/03000605211058864

Ejemplares similares